Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Baxter
Merck
McKinsey
Medtronic

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,787,161

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,787,161
Title: Anti-cancer compounds
Abstract:This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (Queensland, AU)
Assignee: Peplin Biotech Pty. Ltd. (Fortitude Valley, AU)
Application Number:09/888,178
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,787,161
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 6,787,161

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,787,161

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPO8640Aug 19, 1997

International Family Members for US Patent 6,787,161

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 397580   Start Trial
Australia 736230   Start Trial
Australia 8721798   Start Trial
Brazil 9811327   Start Trial
Canada 2301082   Start Trial
China 1266421   Start Trial
Cyprus 1108303   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Colorcon
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.